Apogee Therapeutics, Inc.
APGE
株式のランク
#2356
Apogee Therapeutics, Inc. is a biotechnology firm, operating via its... Apogee Therapeutics, Inc. is a biotechnology firm, operating via its subsidiary, dedicated to advancing biologic treatments for conditions such as atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and a range of other inflammatory and immunological disorders. Its primary focus includes APG777, a subcutaneous (SQ) monoclonal antibody (mAb) engineered for an extended half-life to treat AD, and APG808, a similarly formulated SQ extended half-life mAb targeting COPD. Furthermore, its earlier-stage pipeline features APG990, another SQ extended half-life mAb designed for AD, and APG222, comprising extended half-life subcutaneous antibodies also aimed at AD. Established in 2022, the company maintains its headquarters in Waltham, Massachusetts.
株価
$135.07
最終同期: 2026-09-04
時価総額
$8.36B
変化（1日）
0.00%
変化（1年）
144.91%
国
US
取引 Apogee Therapeutics, Inc. (APGE)
カテゴリー
Healthcare
Apogee Therapeutics, Inc.（APGE）のEPS
June 2026 時点のEPS TTM: $-4.34
Apogee Therapeutics, Inc.の最新の財務報告と株価によると、同社の現在のEPS（TTM）は$-4.34です。2023年末には、EPSは$-1.66で、2022年のEPS$-0.79と増加でした。
Apogee Therapeutics, Inc.のEPS履歴（2022から2026まで）
各年末時点のEPS
| 年 | EPS | 変化 |
|---|---|---|
| 2026 (TTM) | $-4.34 | 31.52% |
| 2024 | $-3.30 | 98.80% |
| 2023 | $-1.66 | 110.13% |
| 2022 | $-0.79 | 0.00% |
同様の企業または競合他社のEPS
| 企業 | EPS | EPSの差 | 国 |
|---|---|---|---|
| $17.32 | -499.08% |
US
|
|
| $-7.98 | 83.87% |
US
|
|
| $-5.29 | 21.89% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -739.17% |
NL
|
